Icahn, after break from biopharma activism, hires Harvard geneticist Richard Mulligan
March 01, 2017 at 09:50 AM EST
The hire signals Carl Icahn may be back to biopharma investing, at a time when biotech valuations are 25 percent off their 2015 highs.
